Figure 3.

Established Myc-CaP Tumors Maintain Her-2/neu Expression and Induce a Systemic Cytotoxic CD8 T Cell Response to Rat-Neu Neoantigen.

(a) Treatment scheme for tumor implantation with either 1 × 10⁶ Myc-CaP/WT or Myc-CaP/Neu cells. Fourteen days after tumor implantation, 1 × 10⁶ high-avidity CFSE-labeled Thy1.2⁺ RNEU_420–429-specific CD8 T cells were adoptively transferred (AT) into the mice. On day 5, tumor-draining lymph nodes (TDLNs) were harvested and analyzed by flow cytometry. (b) Tumor growth curves of mice from Myc-CaP/WT and Myc-CaP/Neu tumor-bearing mice. Average tumor volume (±s.e.m.) for each experimental group. (c) Her-2/neu expression on indicated murine allografts (representative immunohistochemistry; repeated x 2). Scale bar = 50 μm. (d) Percentages of proliferating TCRVβ4⁺ CD8 T cells in indicated tissues (representative flow plots and quantification; n ≥ 3 per group, repeated x 2). (e) Percentages of cytokine production by RNEU-specific TCRVβ4⁺ CD8 T cells in indicated tissues (representative flow plots and quantification; n ≥ 3 per group, repeated x 2). Proliferating TCRVβ4⁺ CD8 T cells, and their cytokine production, were calculated as fraction of TCRVβ4⁺ CD8 T cells.